TransMedics Group

Valuation Analysis

About the Company

TransMedics Group en bref

TransMedics Group (TMDX) is currently trading at 68,76 € with a market capitalization of 2,4 Md €. The trailing P/E ratio stands at 18.03x, with a forward P/E of 23.91x. The 52-week range spans from 52,45 € to 136,14 €; the current price is 49.5% below the yearly high. Year-over-year revenue growth stands at +21.2%. The net profit margin stands at 27.04%.

💰 Dividende

TransMedics Group currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent TransMedics Group (TMDX) au consensus : Acheter. L'objectif de cours moyen est de 101,91 €, soit un potentiel de +48.21% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 65,45 € à 123,92 €.

TransMedics Group : la thèse d'investissement en détail

TransMedics Group (TMDX) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 21.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Return on equity of 45.22% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 27.04%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

With a beta near 1.88, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 33.2% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 48.21% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (33.2%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy TransMedics Group?

Compare top-rated brokers — low fees, trusted providers, fully regulated.